A breakthrough in HIV prevention

Location: 13 sites across Africa, Asia and the Americas

In 2011, Science named the HIV Prevention Trials Network (HPTN) 052 study "Breakthrough of the Year." This was the second year in a row that Science selected a trial for which FHI 360 provided scientific leadership and operational support. HPTN 052 was the first randomized clinical trial to show that providing early antiretroviral therapy to an HIV-infected person can dramatically lower the risk of sexual transmission of HIV to an uninfected partner — reducing the risk of infection by as much as 96 percent. According to Science, one of the premier scientific research journals, the study was selected for its "profound implications for the future response to the AIDS epidemic."